Skip to main content
Linda Vahdat, MD, Oncology, Lebanon, NH

LindaT.VahdatMDMBA

Oncology Lebanon, NH

Breast Cancer

Chief of Cancer Services Memorial Sloan Kettering -Norwalk Hospital Partnership Professor of Medicine, Weill Cornell medicine

Dr. Vahdat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vahdat's full profile

Already have an account?

  • Office

    1 Medical Center Dr
    Lebanon, NH 03756
    Phone+1 603-650-5747

Education & Training

  • Massachusetts Institute of Technology, Sloan School of Management
    Massachusetts Institute of Technology, Sloan School of ManagementMBA, Business, 2012 - 2014
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1987 - 1990
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 1987

Certifications & Licensure

  • NH State Medical License
    NH State Medical License 2022 - 2026
  • VT State Medical License
    VT State Medical License 2023 - 2026
  • NY State Medical License
    NY State Medical License 1988 - 2025
  • CT State Medical License
    CT State Medical License 2017 - 2022
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • Copper Depletion Combats Metastatic Recurrence in High-Risk TNBC
    Copper Depletion Combats Metastatic Recurrence in High-Risk TNBCSeptember 9th, 2024
  • This Clinical Trial Is Testing a Pill for Triple-Negative Breast Cancer
    This Clinical Trial Is Testing a Pill for Triple-Negative Breast CancerAugust 27th, 2024
  • Post-ASCO News Alert: AstraZeneca’s/Merck’s Lynparza Use in Niche HR+ gBRCA-Mutant Breast Cancer Subgroup Could Compete with Verzenio
    Post-ASCO News Alert: AstraZeneca’s/Merck’s Lynparza Use in Niche HR+ gBRCA-Mutant Breast Cancer Subgroup Could Compete with VerzenioJune 21st, 2021
  • Join now to see all